Clinical Trial Update: An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia [Phase 3]

View source ↗

Summary

This document reports an extension Phase 3 trial to evaluate the long-term safety and tolerability of adjunctive KarXT for schizophrenia; recruitment is ongoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Conditions: Schizophrenia | Phase 3 | Status: RECRUITING